Personalizing Immune Checkpoint Inhibitor Therapy

Status Withdrawn

Clinical Trial Summary

This prospective, observational study will evaluate whether vitro testing of tumor tissue and white blood cells from patients with lung cancer who are being treated with immune checkpoint inhibitors and other standard of care approaches, predicts clinical response to these agents.

Clinical Trial Description

Overall Goal: The long-term goal of this study is to predict whether checkpoint inhibitors will be effective in individual patients with solid tumors.

Objectives: In this pilot study to be conducted in ten subjects with lung cancer who are to receive checkpoint inhibitors, we will use cellular and molecular techniques to characterize

- tumor immunogenicity

- anti-tumor T-cell response

- effect of checkpoint inhibitors on antigen presentation and T-cell response, and

- the tumor microenvironment

Planned enrollment:

• Ten subjects with lung cancer

Methods for Informed Consent:

Investigators will approach subjects for informed consent ;

Study Design

Related Conditions & MeSH terms

Lung Cancer Stage IV

Clinical Trial Details

NCT number	NCT03409341
Study type	Observational
Source	Holy Cross Hospital, Maryland
Contact
Status	Withdrawn
Phase
Start date	February 1, 2019
Completion date	September 22, 2020

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03668496` - A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC	Phase 3
Active, not recruiting	`NCT03322072` - Calypso Guided High Precision Stereotactic Ablative Radiosurgery for Lung TUmours Using Real-Time Tumour Tracking & Respiratory Gating	N/A
Recruiting	`NCT05497973` - Psychosocial eHealth in Advanced Lung Cancer	N/A
Recruiting	`NCT06076005` - Lung Cancer ID (Identity) Study
Recruiting	`NCT05860296` - Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers	Phase 1/Phase 2
Recruiting	`NCT05311709` - Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities	Phase 2
Completed	`NCT04825912` - Resilience Measurement in Older Adults With Late-Stage Lung Cancer	N/A
Completed	`NCT03529851` - Feasibility of a Web-based Patient Reported Outcome Symptom Monitoring Application in Danish Lung Cancer Patients	N/A
Completed	`NCT03558165` - Lung Cancer Next Generation Sequencing Using the Oncomine Comprehensive Assay
Completed	`NCT03076164` - A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib	Phase 1/Phase 2
Not yet recruiting	`NCT03153358` - Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation	Phase 2
Recruiting	`NCT04595734` - Liver Toxicity in Lung Cancer Patients Treated With Immune-checkpoint Inhibitors.
Recruiting	`NCT04519983` - Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs	Phase 2
Not yet recruiting	`NCT05701384` - Lazertinib 160mg in EGFR T790M NSCLC	Phase 2
Active, not recruiting	`NCT03728361` - Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer	Phase 2
Not yet recruiting	`NCT06024941` - Re-induction of a Systemic Immune Response in Metastatic or Locally Recurrent Lung Cancer	Phase 2
Recruiting	`NCT04669223` - Comparing Different Sizes of Small-bore Chest Drains in Malignant Pleural Effusion	N/A
Recruiting	`NCT05996263` - Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)
Completed	`NCT04057196` - Self-System Therapy for Older Adults With Lung Cancer	N/A
Recruiting	`NCT06000358` - The Effect of Combined Cryotherapy and Immunotherapy on Systemic T Cell Changes and Clinical Outcomes in Metastatic Non-small Cell Lung Cancer	N/A